Hormonsubstitution efter salpingo-ooforektomi hos BRCA1/2-mutationsbaerere öger ikke risikoen for brystkraeft
Engelsk titel: Hormone replacement therapy after salpingo-oophorectomy in BRCA 1/2 mutation carriers does not increase the risk of breast cancer
Läs online
Författare:
Sörbröden Breda, Astrid
;
Blaakaer, Jan
Email: jab@dadlnet.dk
Språk: Dan
Antal referenser: 12
Dokumenttyp:
Översikt
UI-nummer: 14117465
Sammanfattning
Prophylactic bilateral salpingo-oophorectomy (PBSO) reduces the risk of breast- and ovarian cancer in breast cancer gene (BRCA)1/2 mutation carriers. Women choose
hormone replacement therapy (HT) to alleviate climacteric symptoms. Studies have shown a higher risk of breast cancer in healthy post-menopausal women getting HT. Further
research among women with BRCA1/2 mutations is essential. No studies showed significantly that short-term use of HT alters the reduction in breast cancer risk associated with
PBSO. Neither was there found any significant difference in type of HT chosen.